COMPOSITIONS AND METHODS FOR TREATING TYPE 1 DIABETES Russian patent published in 2021 - IPC C12N1/21 C12N15/09 A61K35/744 A61K35/747 A61K38/20 A61K39/00 A61P3/10 

FIELD: medicine.

SUBSTANCE: group of inventions relates to treatment of type 1 diabetes mellitus (T1D). Proposed is a lactic acid bacterium (LAB) for treating T1D by means of delivery of an interleukin-2 (IL-2) polypeptide and a T1D-specific antigen polypeptide into the mucosa, wherein said LAB comprises an exogenous nucleic acid encoding said IL-2 polypeptide and an exogenous nucleic acid encoding said T1D-specific antigen polypeptide. Said LAB is therein capable of producing said IL-2 polypeptide and said T1D-specific antigen polypeptide. Said T1D-specific antigen polypeptide therein constitutes: proinsulin (PINS), glutamic acid decarboxylase (GAD65), insulinoma-associated protein 2 (IA-2), a catalytic subunit of a bound protein of islet-specific glucose-6-phosphatase (IGRP), a zinc transporter 8 (ZnT8), chromogranin A, a (prepro)islet amyloid polypeptide (ppIAPP), peripherin or a citrullinated glucose-regulated protein (GRP). Also proposed is a composition for treating T1D by delivery of an IL-2 polypeptide and a T1D-specific antigen polypeptide into the mucosa, containing, in an effective amount, (a) a first LAB containing an exogenous nucleic acid encoding said IL-2 polypeptide and capable of producing said IL-2 polypeptide, and (b) a second LAB containing an exogenous nucleic acid encoding said T1D-specific antigen polypeptide and capable of producing said T1D-specific antigen polypeptide. Said LAB or composition are used as part of a pharmaceutical composition and also applied in a method for treating T1D in a mammalian subject in need thereof.

EFFECT: group of inventions ensures stimulation and activation of Treg cells.

40 cl, 23 dwg, 5 tbl, 9 ex